India Glycols' demerger of its Biopharma and Spirits & Biofuel undertakings has been sanctioned by the NCLT, Allahabad. Shareholders will receive shares in the new entities, Ennature Bio Pharma and IGL Spirits. The company also clarified a minor income tax demand which has been discharged.
India Glycols Demerger Approved by NCLT
India Glycols Limited has received final judicial approval from the NCLT, Allahabad Bench, for its Scheme of Arrangement. The approval sanctions the demerger of the company's Biopharma Undertaking and its Spirits and Biofuel Undertaking into two distinct resulting companies: Ennature Bio Pharma Limited and IGL Spirits Limited.
What just happened
The National Company Law Tribunal (NCLT), Allahabad Bench, officially sanctioned the Scheme of Arrangement for India Glycols on July 17, 2026. This scheme, with an appointed date of April 1, 2026, will see the Biopharma and Spirits & Biofuel businesses spun off into separate entities.
Why this matters
This NCLT sanction is the final legal step for the demerger. It will lead to a corporate restructuring, creating focused businesses and issuing new shares to existing India Glycols shareholders, thereby potentially unlocking value and improving operational efficiency for each segment.
Reader Takeaway: Demerger approved, creating new entities; Tax demand clarified, discharged.
The backstory
India Glycols has been working towards this restructuring to segregate its diverse business segments. The company also addressed a reported income tax demand of INR 27,890 for the assessment year 2024-25, clarifying that this amount, comprising an Equalisation Levy of INR 20,976 and interest of INR 6,914, has been fully discharged.
What changes now
Following the scheme's effectiveness, India Glycols shareholders will receive shares in the new entities. For every three equity shares held in India Glycols, shareholders will get one equity share of Ennature Bio Pharma Limited (Rs 5 face value). For every one equity share held in India Glycols, shareholders will receive one equity share of IGL Spirits Limited (Rs 5 face value). The scheme does not involve debt restructuring or a reduction in paid-up capital.
Risks to watch
Shareholders should closely monitor company announcements for the 'Effective Date' of the scheme. Until then, the demerger is not officially implemented. Any delays or changes in the share entitlement ratio could impact investor sentiment.
Peer comparison
Demergers are common strategic moves in the Indian corporate landscape to unlock shareholder value by creating focused entities. Companies like Tata Chemicals (demerging its consumer business into a new entity) and others have undertaken similar restructurings to streamline operations and improve market valuation for distinct business verticals.
Context metrics
The scheme was sanctioned by the NCLT, Allahabad Bench, on July 17, 2026, with an appointed date of April 1, 2026. The income tax demand of INR 27,890 was discharged, with the Equalisation Levy deposited on July 6, 2023, and Form 1 filed on June 25, 2024.
What to track next
Investors should watch for the official 'Effective Date' announcement from India Glycols, which will trigger the share allotment process. Tracking the performance of the newly formed Ennature Bio Pharma Limited and IGL Spirits Limited post-demerger will also be crucial.